Allergan's rapastinel misses as adjunct depression therapy

Allergan said late Wednesday that rapastinel as adjunctive therapy missed the primary endpoint in three Phase III trials for the acute treatment of major depressive disorder (MDD).

Allergan plc (NYSE:AGN) is also conducting a Phase III program evaluating rapastinel as monotherapy to treat MDD, and a Phase II trial of rapastinel plus standard of care (SOC) in MDD patients at imminent risk of suicide. The company said Wednesday it will evaluate the effect of the acute MDD trials on the monotherapy program and suicidality trial, and expects to make a decision on all of the programs this year...